Physician profile
John B Bedotto
NPI 1164468385
$19,994.49
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2021: $148 · 2022: $1,279 · 2023: $139 · 2024: $90.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $228.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $11,079.99 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $6,789.99 | 2019 | |
| Amgen INC. | $937.50 | 2021-2024 | Repatha |
| Akcea Therapeutics, INC. | $379.90 | 2019 | |
| Atricure, INC. | $155.75 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $120.06 | 2022 | |
| Pfizer INC. | $107.36 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.45 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $82.91 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $82.53 | 2023 | Lifevest |
| Philips North America LLC | $81.30 | 2023-2024 | (5091) Amb Mon & Diag Und |
| Boston Scientific Corporation | $29.23 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $27.99 | 2021 | |
| Lantheus Medical Imaging, INC. | $18.53 | 2023 | Definity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bedotto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.